Abbott Laboratories is leaning into the Make America Healthy Movement, launching a new infant formula made with whole milk.

Abbott Laboratories (NYSE:ABT) launched Similac 360 Total Care Made With Whole Milk, a commercially sterile ready-to-feed liquid infant formula made with whole milk in the U.S. The product is the first of its kind in the U.S. market to combine whole milk with a ready-to-feed liquid format. The formula uses whole milk and a blend of human milk oligosaccharides to more closely mirror key elements of breast milk. The launch expands Abbott

Why the Libre Duo 10 Day approval matters for Abbott Laboratories stock Abbott Laboratories (ABT) drew fresh attention after the FDA authorized its Libre Duo 10 Day dual glucose ketone sensor for people with diabetes, a milestone that broadens the company’s diabetes technology footprint. The system is designed to continuously track glucose and ketone levels, with alerts for rising ketones that may signal risk of diabetic ketoacidosis. Investors now have a new product to watch as Abbott...

Abbott Laboratories stock trades a little above $111 after a recent European approval for its Amulet

Price-action only: Abbott Laboratories (ABT) movements set the tone for institutional models. Precision Trading with Abbott Laboratories (ABT) Risk Zones

Earlier this week, Abbott Laboratories received FDA De Novo authorization for its Libre Duo 10 Day system, a first-of-its-kind wearable that continuously monitors both glucose and ketone levels in people with diabetes aged 2 and older, with a U.S. launch planned later this year and integration into major insulin pump ecosystems. This dual glucose‑ketone sensor introduces a new integrated continuous glucose and ketone monitoring standard in the U.S., potentially strengthening Abbott’s digital...

Abbott is aiming to capture share from Boston Scientific in the market for devices that seal the heart’s left atrial appendage to reduce stroke risk.

Abbott (ABT) concluded the recent trading session at $111.59, signifying a -2.2% move from its prior day

Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it will actually take to close that gap.